Researchers cautioned that study results involving laboratory mouse models do not always translate into clinical treatment of human patients
Researchers used blood platelets and bone marrow cells to deliver potentially curative
to mouse models of the human genetic disorder Hurler syndrome – an often fatal condition that causes organ damage and other medical complications.
Scientists from Cincinnati Children’s Hospital Medical Center and the National Institute of Neurological Disorders and Stroke (NINDS) report their unique strategy for treating the disease the week of Feb. 3-7 in Proceedings of the National Academy of Sciences (PNAS).
Researchers were able to genetically insert into the cells a gene that produces a critical lysosomal enzyme (called IDUA) and then inject the engineered cells into mice to treat the disorder. Follow up tests showed the treatment resulted in a complete metabolic correction of the disease, according to the authors.
“Our findings demonstrate a unique and somewhat surprising delivery pathway for lysosomal enzymes,” said Dao Pan, PhD, corresponding author and researcher in the Division of Experimental Hematology and Cancer Biology at Cincinnati Children’s. “We show proof of concept that platelets and megakaryocytes are capable of generating and storing fully functional lysosomal enzymes, which can lead to their targeted and efficient delivery to vital tissues where they are needed.”
The mice tested in the study modeled human Hurler syndrome, a subset of disease known as mucopolysaccharidosis type I (MPS I), one of the most common types of lysosomal storage diseases. MPS I is a lysosomal storage disease in which people do not make an enzyme called lysosomal alpha-L-iduronidase (IDUA).
IDUA helps break down sugar molecules found throughout the body, often in mucus and fluids around joints, according to the National Library of Medicine/National Institutes of Health. Without IDUA, sugar molecules build up and cause organ damage. Depending on severity, the syndrome can also cause deafness, abnormal bone growth, heart valve problems, joint disease, intellectual disabilities and death.
Enzyme replacement therapy can be used to treat the disease, but it is only temporary and not curative. Bone marrow transplant using hematopoietic stem cells also has been tested on some patients with mixed results. The transplant procedure can carry severe risks and does not always work.
Pan and her colleagues – including Roscoe O. Brady, MD, a researcher at NINDS – report that using platelets and megakaryocytes for gene therapy is effective and could reduce the risk of activating cancer-causing oncogenes in hematopoietic stem cells.
The authors said tests showed that human megakaryocytic cells were capable of overexpressing IDUA, revealing their capacity for potential therapeutic benefit. While engineering megakaryocytes and platelets for infusion into their mouse models of Hurler, the scientists report they were able to release IDUA directly into amply sized extracellular spaces or inside micro-particles as the cells matured or activated. The cells were able to produce and package large amounts of functional IDUA and retained the capacity to cross-correct patient cells.
After infusing mouse models of Hurler with the genetically modified cells, researchers said this led to long-term normalization of IDUA levels in the animal’s blood with versatile delivery routes and on-target preferential distribution to the liver and spleen. The treatment led to a complete metabolic correction of MPS I in most peripheral organs of the mice.
Researchers cautioned that study results involving laboratory mouse models do not always translate into clinical treatment of human patients, and that additional research is needed for this prospective therapy.
The Latest on: Hurler syndrome
via Google News
The Latest on: Hurler syndrome
- "Do we have enough for a cure now?" 7-year-old girl's lemonade stand raises over $1000 for her little brotheron May 16, 2021 at 12:22 pm
A 7-year-old girl created a lemonade stand on Saturday to raise money for her 4-year-old brother's rare genetic disease. She aimed to raise $150 - and was overcome when the kindness of strangers ...
- Help is on the way for Hoosier home careon May 14, 2021 at 4:05 pm
Help is on the way for Hoosiers needing medical attention at home. For years, Indiana has faced a shortage of nurses in direct care. Lawmakers addressed the problem in the 2021 ...
- Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updateson May 13, 2021 at 4:04 am
Commercial Activities Advancing for Upcoming Launch of LibmeldyTM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany Update on OTL-200 U.S. BLA Filing Strategy for MLD on ...
- Orchard Therapeutics plc (ORTX)on April 30, 2021 at 8:16 am
$150M Strategic Financing Supports Execution into the First Half of 2023 OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by Year End ...
- JCR PHARMACEUTICAL CO (JCRRF)on April 23, 2021 at 3:23 pm
JCR announced that EMA has granted orphan drug designation to JR-171, an investigational drug for the treatment of Hurler syndrome (MPS 1). JCR Pharmaceutical announced that the Ministry of Health ...
- Comprehensive Farber Disease Epidemiology insight of the Farber's Disease and its treatment.on April 16, 2021 at 9:31 pm
Synthetic versions of missing enzymes have been developed and used to treat individuals with certain lysosomal diseases including Hurler syndrome, Fabry disease, and Gaucher disease. Clinical ...
- ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS Ion April 14, 2021 at 5:00 pm
MPS I affects approximately 3,000-4,000 patients worldwide. The most severe form of MPS I, Hurler syndrome affects several organs, including the brain, resulting in somatic and neurological ...
- JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japanon March 23, 2021 at 4:33 am
Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler syndrome, Hurler-Scheie, and Scheie syndrome), MPS II (Hunter syndrome), Pompe ...
- Hunter syndromeon November 15, 2020 at 3:00 pm
and is tipped Hunter syndrome was able to induce expression of the IDS enzyme that is deficient in the disease. ... was able to induce expression of the IDUA enzyme missing in the disease, which is ...
- Orchard Therapeutics PLC - ADRon November 9, 2019 at 9:36 am
March 2 (Reuters) - Orchard Therapeutics PLC ::ORCHARD THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND REVIEWS RECENT ACCOMPLISHMENTS.ORCHARD THERAPEUTICS PLC - $150 MILLION STRATEGIC ...
via Bing News